 BetterLife Pharma Inc CSE:BETR OTCQB:BETRF FRA:NPAU announced it has received funding from the Mitacs Accelerate program to research the anti-depressant effects of an LSD derivative. TD-1048A is a second-generation LSD derivative molecule that could offer therapeutic effects without any psychoactive reactions like hallucinations commonly associated with the psychedelic compound. 